Eritel 20 Tablet contains Erlotinib 150 mg, a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Erlotinib acts by selectively inhibiting the intracellular phosphorylation of EGFR, thereby blocking downstream signaling pathways involved in tumor cell proliferation, survival, and metastasis. Indicated for patients with locally advanced or metastatic NSCLC with activating EGFR mutations and for use in combination with gemcitabine in locally advanced, unresectable, or metastatic pancreatic cancer, Eritel 20 Tablet offers targeted therapy that improves progression-free survival. The medication is administered orally, with dosage and duration tailored according to the patient’s clinical condition and response. Common adverse effects include rash, diarrhea, anorexia, and fatigue, while serious toxicities may involve interstitial lung disease and hepatotoxicity, warranting close monitoring. Patients should be advised to avoid concomitant use of strong CYP3A4 inducers or inhibitors and to report any signs of severe skin reactions or respiratory symptoms promptly. Eritel 20 Tablet should be prescribed and supervised by oncology specialists, ensuring appropriate patient selection and management to optimize therapeutic outcomes.